nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Mycophenolate mofetil—systemic scleroderma	0.109	0.157	CbGbCtD
Dabrafenib—ABCG2—Leflunomide—systemic scleroderma	0.0814	0.118	CbGbCtD
Dabrafenib—CYP2C8—Mometasone—systemic scleroderma	0.0673	0.0973	CbGbCtD
Dabrafenib—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.0633	0.0915	CbGbCtD
Dabrafenib—SLC22A6—Captopril—systemic scleroderma	0.0517	0.0747	CbGbCtD
Dabrafenib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0503	0.0727	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—systemic scleroderma	0.0436	0.063	CbGbCtD
Dabrafenib—ABCB1—Lisinopril—systemic scleroderma	0.0308	0.0445	CbGbCtD
Dabrafenib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0268	0.0387	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—systemic scleroderma	0.0254	0.0367	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—systemic scleroderma	0.0234	0.0339	CbGbCtD
Dabrafenib—ABCB1—Captopril—systemic scleroderma	0.023	0.0333	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—systemic scleroderma	0.0202	0.0292	CbGbCtD
Dabrafenib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0181	0.0262	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—systemic scleroderma	0.0163	0.0236	CbGbCtD
Dabrafenib—ABCB1—Prednisone—systemic scleroderma	0.0145	0.021	CbGbCtD
Dabrafenib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0109	0.0157	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—systemic scleroderma	0.00869	0.0126	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—systemic scleroderma	0.00727	0.0105	CbGbCtD
Dabrafenib—NEK11—lung—systemic scleroderma	0.00227	0.121	CbGeAlD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.00227	0.0312	CbGpPWpGaD
Dabrafenib—LIMK1—tendon—systemic scleroderma	0.00185	0.0985	CbGeAlD
Dabrafenib—SIK1—Circadian rythm related genes—TOP1—systemic scleroderma	0.00182	0.025	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by focal adhesion kinase—GIT2—systemic scleroderma	0.00175	0.024	CbGpPWpGaD
Dabrafenib—BRAF—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.0017	0.0234	CbGpPWpGaD
Dabrafenib—LIMK1—Semaphorin interactions—RHOB—systemic scleroderma	0.0017	0.0233	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.00166	0.0227	CbGpPWpGaD
Dabrafenib—LIMK1—Regulation of actin dynamics for phagocytic cup formation—CD247—systemic scleroderma	0.00165	0.0227	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.00142	0.0194	CbGpPWpGaD
Dabrafenib—SIK1—connective tissue—systemic scleroderma	0.00139	0.0741	CbGeAlD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.00129	0.0177	CbGpPWpGaD
Dabrafenib—SIK1—skin of body—systemic scleroderma	0.00126	0.0669	CbGeAlD
Dabrafenib—LIMK1—Fcgamma receptor (FCGR) dependent phagocytosis—CD247—systemic scleroderma	0.00125	0.0171	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.00121	0.0167	CbGpPWpGaD
Dabrafenib—RAF1—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.00118	0.0162	CbGpPWpGaD
Dabrafenib—BRAF—tendon—systemic scleroderma	0.00114	0.0609	CbGeAlD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.00112	0.0154	CbGpPWpGaD
Dabrafenib—RAF1—connective tissue—systemic scleroderma	0.00111	0.059	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—systemic scleroderma	0.00102	0.054	CbGeAlD
Dabrafenib—BRAF—lung—systemic scleroderma	0.001	0.0534	CbGeAlD
Dabrafenib—RAF1—skin of body—systemic scleroderma	0.001	0.0533	CbGeAlD
Dabrafenib—SIK1—tendon—systemic scleroderma	0.000958	0.051	CbGeAlD
Dabrafenib—SLCO1B3—lung—systemic scleroderma	0.000866	0.046	CbGeAlD
Dabrafenib—SIK1—lung—systemic scleroderma	0.000841	0.0447	CbGeAlD
Dabrafenib—LIMK1—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000816	0.0112	CbGpPWpGaD
Dabrafenib—RAF1—GMCSF-mediated signaling events—IRF8—systemic scleroderma	0.000809	0.0111	CbGpPWpGaD
Dabrafenib—RAF1—digestive system—systemic scleroderma	0.000802	0.0426	CbGeAlD
Dabrafenib—RAF1—tendon—systemic scleroderma	0.000763	0.0406	CbGeAlD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000753	0.0103	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.000736	0.0101	CbGpPWpGaD
Dabrafenib—BRAF—Bladder Cancer—MMP1—systemic scleroderma	0.000675	0.00926	CbGpPWpGaD
Dabrafenib—RAF1—lung—systemic scleroderma	0.000669	0.0356	CbGeAlD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.000648	0.00889	CbGpPWpGaD
Dabrafenib—SLCO1B1—digestive system—systemic scleroderma	0.0006	0.0319	CbGeAlD
Dabrafenib—RAF1—Endothelins—COL1A2—systemic scleroderma	0.000582	0.00799	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000573	0.00786	CbGpPWpGaD
Dabrafenib—BRAF—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.000561	0.0077	CbGpPWpGaD
Dabrafenib—RAF1—BCR signaling pathway—CSK—systemic scleroderma	0.000535	0.00734	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000531	0.00729	CbGpPWpGaD
Dabrafenib—RAF1—Endothelin Pathways—EDN1—systemic scleroderma	0.000528	0.00725	CbGpPWpGaD
Dabrafenib—BRAF—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.000528	0.00724	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.000509	0.00699	CbGpPWpGaD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.0005	0.00687	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—RHOB—systemic scleroderma	0.000481	0.00661	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000469	0.00644	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.000448	0.00615	CbGpPWpGaD
Dabrafenib—ABCB1—blood vessel—systemic scleroderma	0.000442	0.0235	CbGeAlD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.000441	0.00606	CbGpPWpGaD
Dabrafenib—LIMK1—EPH-Ephrin signaling—MMP2—systemic scleroderma	0.00043	0.0059	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000408	0.00561	CbGpPWpGaD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000408	0.0056	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CD247—systemic scleroderma	0.000397	0.00545	CbGpPWpGaD
Dabrafenib—RAF1—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.000388	0.00533	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000381	0.00524	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—RHOB—systemic scleroderma	0.000369	0.00506	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000368	0.00506	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000367	0.00504	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.000365	0.00502	CbGpPWpGaD
Dabrafenib—RAF1—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.000365	0.00501	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	0.000361	0.00496	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.000354	0.00485	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—COL1A2—systemic scleroderma	0.000348	0.00477	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000346	0.00475	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—RHOB—systemic scleroderma	0.000343	0.00471	CbGpPWpGaD
Dabrafenib—RAF1—GMCSF-mediated signaling events—CCL2—systemic scleroderma	0.00033	0.00452	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000325	0.00446	CbGpPWpGaD
Dabrafenib—LIMK1—EPH-Ephrin signaling—MMP9—systemic scleroderma	0.000323	0.00444	CbGpPWpGaD
Dabrafenib—RAF1—Endothelin Pathways—NOS3—systemic scleroderma	0.000322	0.00442	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.000322	0.00442	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—ITGAM—systemic scleroderma	0.000316	0.00433	CbGpPWpGaD
Dabrafenib—RAF1—Endothelins—EDN1—systemic scleroderma	0.000315	0.00432	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000301	0.00413	CbGpPWpGaD
Dabrafenib—RAF1—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000298	0.00409	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—BLK—systemic scleroderma	0.000292	0.00401	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000283	0.00388	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000282	0.00387	CbGpPWpGaD
Dabrafenib—ABCG2—lung—systemic scleroderma	0.000277	0.0147	CbGeAlD
Dabrafenib—RAF1—Endothelins—MMP1—systemic scleroderma	0.000265	0.00363	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000265	0.00363	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000264	0.00362	CbGpPWpGaD
Dabrafenib—BRAF—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000261	0.00358	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—ITGAM—systemic scleroderma	0.00026	0.00356	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD247—systemic scleroderma	0.00026	0.00356	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000258	0.00354	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—RHOB—systemic scleroderma	0.000255	0.0035	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00025	0.00344	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—CSK—systemic scleroderma	0.000244	0.00335	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000243	0.00334	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000242	0.00332	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000242	0.00332	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—COL1A2—systemic scleroderma	0.000241	0.0033	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00024	0.00111	CcSEcCtD
Dabrafenib—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000239	0.0011	CcSEcCtD
Dabrafenib—Abdominal pain—Captopril—systemic scleroderma	0.000239	0.0011	CcSEcCtD
Dabrafenib—Body temperature increased—Captopril—systemic scleroderma	0.000239	0.0011	CcSEcCtD
Dabrafenib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000238	0.0011	CcSEcCtD
Dabrafenib—Oedema—Mycophenolic acid—systemic scleroderma	0.000237	0.0011	CcSEcCtD
Dabrafenib—Dry skin—Prednisone—systemic scleroderma	0.000237	0.00109	CcSEcCtD
Dabrafenib—Nausea—Pentoxifylline—systemic scleroderma	0.000237	0.00109	CcSEcCtD
Dabrafenib—Chills—Mycophenolate mofetil—systemic scleroderma	0.000237	0.00109	CcSEcCtD
Dabrafenib—Infection—Mycophenolic acid—systemic scleroderma	0.000236	0.00109	CcSEcCtD
Dabrafenib—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000235	0.00109	CcSEcCtD
Dabrafenib—RAF1—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000235	0.00323	CbGpPWpGaD
Dabrafenib—Diarrhoea—Mometasone—systemic scleroderma	0.000235	0.00109	CcSEcCtD
Dabrafenib—Hypokalaemia—Prednisone—systemic scleroderma	0.000235	0.00109	CcSEcCtD
Dabrafenib—Leukopenia—Lisinopril—systemic scleroderma	0.000234	0.00108	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—systemic scleroderma	0.000234	0.00108	CcSEcCtD
Dabrafenib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000233	0.00108	CcSEcCtD
Dabrafenib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000233	0.00107	CcSEcCtD
Dabrafenib—Hypotension—Leflunomide—systemic scleroderma	0.000232	0.00107	CcSEcCtD
Dabrafenib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000232	0.00107	CcSEcCtD
Dabrafenib—CYP3A4—digestive system—systemic scleroderma	0.000231	0.0123	CbGeAlD
Dabrafenib—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000231	0.00107	CcSEcCtD
Dabrafenib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00023	0.00106	CcSEcCtD
Dabrafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.00023	0.00315	CbGpPWpGaD
Dabrafenib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000229	0.00106	CcSEcCtD
Dabrafenib—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000229	0.00106	CcSEcCtD
Dabrafenib—Cough—Lisinopril—systemic scleroderma	0.000229	0.00106	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000228	0.00105	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000227	0.00105	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000227	0.00105	CcSEcCtD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000226	0.0031	CbGpPWpGaD
Dabrafenib—Insomnia—Leflunomide—systemic scleroderma	0.000225	0.00104	CcSEcCtD
Dabrafenib—Arthralgia—Lisinopril—systemic scleroderma	0.000223	0.00103	CcSEcCtD
Dabrafenib—Myalgia—Lisinopril—systemic scleroderma	0.000223	0.00103	CcSEcCtD
Dabrafenib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000222	0.00102	CcSEcCtD
Dabrafenib—Hypotension—Mycophenolic acid—systemic scleroderma	0.000222	0.00102	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000221	0.00102	CcSEcCtD
Dabrafenib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000221	0.00102	CcSEcCtD
Dabrafenib—Pancreatitis—Prednisone—systemic scleroderma	0.000219	0.00101	CcSEcCtD
Dabrafenib—Vomiting—Mometasone—systemic scleroderma	0.000218	0.00101	CcSEcCtD
Dabrafenib—RAF1—Focal Adhesion—ITGAM—systemic scleroderma	0.000218	0.003	CbGpPWpGaD
Dabrafenib—Dry mouth—Lisinopril—systemic scleroderma	0.000218	0.00101	CcSEcCtD
Dabrafenib—Rash—Mometasone—systemic scleroderma	0.000217	0.001	CcSEcCtD
Dabrafenib—Asthenia—Captopril—systemic scleroderma	0.000217	0.001	CcSEcCtD
Dabrafenib—Dermatitis—Mometasone—systemic scleroderma	0.000216	0.001	CcSEcCtD
Dabrafenib—Decreased appetite—Leflunomide—systemic scleroderma	0.000216	0.000999	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000216	0.000998	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000215	0.000995	CcSEcCtD
Dabrafenib—Headache—Mometasone—systemic scleroderma	0.000215	0.000994	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000215	0.000992	CcSEcCtD
Dabrafenib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000215	0.000991	CcSEcCtD
Dabrafenib—Fatigue—Leflunomide—systemic scleroderma	0.000214	0.00099	CcSEcCtD
Dabrafenib—Oedema—Lisinopril—systemic scleroderma	0.000214	0.000987	CcSEcCtD
Dabrafenib—Pruritus—Captopril—systemic scleroderma	0.000214	0.000986	CcSEcCtD
Dabrafenib—RAF1—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000213	0.00292	CbGpPWpGaD
Dabrafenib—Constipation—Leflunomide—systemic scleroderma	0.000213	0.000982	CcSEcCtD
Dabrafenib—Infection—Lisinopril—systemic scleroderma	0.000212	0.000981	CcSEcCtD
Dabrafenib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000979	CcSEcCtD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.00021	0.00288	CbGpPWpGaD
Dabrafenib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000209	0.000966	CcSEcCtD
Dabrafenib—Neutropenia—Prednisone—systemic scleroderma	0.000209	0.000964	CcSEcCtD
Dabrafenib—Abdominal pain—Azathioprine—systemic scleroderma	0.000208	0.000962	CcSEcCtD
Dabrafenib—Body temperature increased—Azathioprine—systemic scleroderma	0.000208	0.000962	CcSEcCtD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000208	0.00286	CbGpPWpGaD
Dabrafenib—Skin disorder—Lisinopril—systemic scleroderma	0.000208	0.000959	CcSEcCtD
Dabrafenib—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000207	0.000954	CcSEcCtD
Dabrafenib—Diarrhoea—Captopril—systemic scleroderma	0.000206	0.000954	CcSEcCtD
Dabrafenib—BRAF—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000206	0.00284	CbGpPWpGaD
Dabrafenib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000206	0.000953	CcSEcCtD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000206	0.00283	CbGpPWpGaD
Dabrafenib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000205	0.000949	CcSEcCtD
Dabrafenib—RAF1—SHP2 signaling—NOS3—systemic scleroderma	0.000205	0.00281	CbGpPWpGaD
Dabrafenib—BRAF—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000205	0.00281	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000205	0.000946	CcSEcCtD
Dabrafenib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000205	0.000945	CcSEcCtD
Dabrafenib—Nausea—Mometasone—systemic scleroderma	0.000204	0.000943	CcSEcCtD
Dabrafenib—RAF1—Signaling by Interleukins—IL1A—systemic scleroderma	0.000203	0.00279	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000203	0.000939	CcSEcCtD
Dabrafenib—Constipation—Mycophenolic acid—systemic scleroderma	0.000203	0.000937	CcSEcCtD
Dabrafenib—RAF1—Focal Adhesion—BLK—systemic scleroderma	0.000202	0.00277	CbGpPWpGaD
Dabrafenib—Hyperglycaemia—Prednisone—systemic scleroderma	0.000201	0.00093	CcSEcCtD
Dabrafenib—Cough—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000925	CcSEcCtD
Dabrafenib—Hypotension—Lisinopril—systemic scleroderma	0.0002	0.000922	CcSEcCtD
Dabrafenib—Dizziness—Captopril—systemic scleroderma	0.0002	0.000922	CcSEcCtD
Dabrafenib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000915	CcSEcCtD
Dabrafenib—RAF1—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000197	0.00271	CbGpPWpGaD
Dabrafenib—Abdominal pain—Leflunomide—systemic scleroderma	0.000197	0.000908	CcSEcCtD
Dabrafenib—Body temperature increased—Leflunomide—systemic scleroderma	0.000197	0.000908	CcSEcCtD
Dabrafenib—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000196	0.00269	CbGpPWpGaD
Dabrafenib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000902	CcSEcCtD
Dabrafenib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000902	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000195	0.000899	CcSEcCtD
Dabrafenib—Hypersensitivity—Azathioprine—systemic scleroderma	0.000194	0.000896	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000194	0.000896	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000896	CcSEcCtD
Dabrafenib—Insomnia—Lisinopril—systemic scleroderma	0.000193	0.000893	CcSEcCtD
Dabrafenib—Vomiting—Captopril—systemic scleroderma	0.000192	0.000886	CcSEcCtD
Dabrafenib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000882	CcSEcCtD
Dabrafenib—Rash—Captopril—systemic scleroderma	0.00019	0.000879	CcSEcCtD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.00019	0.00261	CbGpPWpGaD
Dabrafenib—Dermatitis—Captopril—systemic scleroderma	0.00019	0.000878	CcSEcCtD
Dabrafenib—Headache—Captopril—systemic scleroderma	0.000189	0.000873	CcSEcCtD
Dabrafenib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000188	0.000866	CcSEcCtD
Dabrafenib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000188	0.000866	CcSEcCtD
Dabrafenib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000865	CcSEcCtD
Dabrafenib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000859	CcSEcCtD
Dabrafenib—Decreased appetite—Lisinopril—systemic scleroderma	0.000186	0.000858	CcSEcCtD
Dabrafenib—RAF1—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000185	0.00254	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000185	0.000852	CcSEcCtD
Dabrafenib—Fatigue—Lisinopril—systemic scleroderma	0.000184	0.000851	CcSEcCtD
Dabrafenib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000848	CcSEcCtD
Dabrafenib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000847	CcSEcCtD
Dabrafenib—Hypersensitivity—Leflunomide—systemic scleroderma	0.000183	0.000846	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—systemic scleroderma	0.000183	0.000845	CcSEcCtD
Dabrafenib—Constipation—Lisinopril—systemic scleroderma	0.000183	0.000844	CcSEcCtD
Dabrafenib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000182	0.00084	CcSEcCtD
Dabrafenib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000836	CcSEcCtD
Dabrafenib—RAF1—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000181	0.00248	CbGpPWpGaD
Dabrafenib—Diarrhoea—Azathioprine—systemic scleroderma	0.00018	0.000832	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisone—systemic scleroderma	0.00018	0.000829	CcSEcCtD
Dabrafenib—Nausea—Captopril—systemic scleroderma	0.000179	0.000828	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000179	0.000826	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisone—systemic scleroderma	0.000179	0.000825	CcSEcCtD
Dabrafenib—Asthenia—Leflunomide—systemic scleroderma	0.000178	0.000824	CcSEcCtD
Dabrafenib—Pruritus—Leflunomide—systemic scleroderma	0.000176	0.000813	CcSEcCtD
Dabrafenib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000176	0.000811	CcSEcCtD
Dabrafenib—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000808	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000175	0.000807	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—systemic scleroderma	0.000174	0.000806	CcSEcCtD
Dabrafenib—Dizziness—Azathioprine—systemic scleroderma	0.000174	0.000804	CcSEcCtD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000174	0.00239	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000788	CcSEcCtD
Dabrafenib—Asthenia—Mycophenolic acid—systemic scleroderma	0.00017	0.000786	CcSEcCtD
Dabrafenib—Diarrhoea—Leflunomide—systemic scleroderma	0.00017	0.000786	CcSEcCtD
Dabrafenib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000782	CcSEcCtD
Dabrafenib—RAF1—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000169	0.00232	CbGpPWpGaD
Dabrafenib—Body temperature increased—Lisinopril—systemic scleroderma	0.000169	0.00078	CcSEcCtD
Dabrafenib—Abdominal pain—Lisinopril—systemic scleroderma	0.000169	0.00078	CcSEcCtD
Dabrafenib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000168	0.000775	CcSEcCtD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000168	0.0023	CbGpPWpGaD
Dabrafenib—Vomiting—Azathioprine—systemic scleroderma	0.000167	0.000773	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—systemic scleroderma	0.000167	0.000771	CcSEcCtD
Dabrafenib—RAF1—Leptin signaling pathway—NOS3—systemic scleroderma	0.000167	0.00229	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—RHOB—systemic scleroderma	0.000166	0.00228	CbGpPWpGaD
Dabrafenib—Infestation NOS—Methotrexate—systemic scleroderma	0.000166	0.000768	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—systemic scleroderma	0.000166	0.000768	CcSEcCtD
Dabrafenib—Rash—Azathioprine—systemic scleroderma	0.000166	0.000767	CcSEcCtD
Dabrafenib—Dermatitis—Azathioprine—systemic scleroderma	0.000166	0.000766	CcSEcCtD
Dabrafenib—Headache—Azathioprine—systemic scleroderma	0.000165	0.000762	CcSEcCtD
Dabrafenib—Dizziness—Leflunomide—systemic scleroderma	0.000164	0.00076	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—systemic scleroderma	0.000164	0.000755	CcSEcCtD
Dabrafenib—ABCB1—digestive system—systemic scleroderma	0.000163	0.00869	CbGeAlD
Dabrafenib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000752	CcSEcCtD
Dabrafenib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000162	0.00075	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—systemic scleroderma	0.000162	0.000749	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—systemic scleroderma	0.000162	0.000749	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000747	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—systemic scleroderma	0.000161	0.000745	CcSEcCtD
Dabrafenib—LIMK1—Immune System—CSK—systemic scleroderma	0.000161	0.00221	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.00016	0.0022	CbGpPWpGaD
Dabrafenib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00016	0.00074	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—MMP2—systemic scleroderma	0.00016	0.00219	CbGpPWpGaD
Dabrafenib—Arrhythmia—Prednisone—systemic scleroderma	0.00016	0.000737	CcSEcCtD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000159	0.00218	CbGpPWpGaD
Dabrafenib—Haematuria—Methotrexate—systemic scleroderma	0.000159	0.000732	CcSEcCtD
Dabrafenib—LIMK1—Immune System—IRF5—systemic scleroderma	0.000158	0.00217	CbGpPWpGaD
Dabrafenib—Vomiting—Leflunomide—systemic scleroderma	0.000158	0.00073	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—systemic scleroderma	0.000158	0.000729	CcSEcCtD
Dabrafenib—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000158	0.00216	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Lisinopril—systemic scleroderma	0.000157	0.000727	CcSEcCtD
Dabrafenib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000157	0.000725	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—systemic scleroderma	0.000157	0.000725	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000157	0.00215	CbGpPWpGaD
Dabrafenib—Rash—Leflunomide—systemic scleroderma	0.000157	0.000724	CcSEcCtD
Dabrafenib—Dermatitis—Leflunomide—systemic scleroderma	0.000157	0.000724	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—systemic scleroderma	0.000157	0.000723	CcSEcCtD
Dabrafenib—Nausea—Azathioprine—systemic scleroderma	0.000156	0.000723	CcSEcCtD
Dabrafenib—Headache—Leflunomide—systemic scleroderma	0.000156	0.00072	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—systemic scleroderma	0.000156	0.000718	CcSEcCtD
Dabrafenib—Erythema—Prednisone—systemic scleroderma	0.000156	0.000718	CcSEcCtD
Dabrafenib—RAF1—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.000155	0.00213	CbGpPWpGaD
Dabrafenib—Asthenia—Lisinopril—systemic scleroderma	0.000153	0.000708	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000707	CcSEcCtD
Dabrafenib—LIMK1—Immune System—IRF8—systemic scleroderma	0.000151	0.00208	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ITGAM—systemic scleroderma	0.000151	0.00208	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD247—systemic scleroderma	0.000151	0.00208	CbGpPWpGaD
Dabrafenib—Pruritus—Lisinopril—systemic scleroderma	0.000151	0.000698	CcSEcCtD
Dabrafenib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000151	0.000697	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—systemic scleroderma	0.00015	0.000693	CcSEcCtD
Dabrafenib—Rash—Mycophenolic acid—systemic scleroderma	0.00015	0.000691	CcSEcCtD
Dabrafenib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000149	0.00069	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—systemic scleroderma	0.000149	0.00069	CcSEcCtD
Dabrafenib—Headache—Mycophenolic acid—systemic scleroderma	0.000149	0.000687	CcSEcCtD
Dabrafenib—RAF1—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000148	0.00204	CbGpPWpGaD
Dabrafenib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000684	CcSEcCtD
Dabrafenib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000684	CcSEcCtD
Dabrafenib—Nausea—Leflunomide—systemic scleroderma	0.000148	0.000682	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000147	0.000681	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—systemic scleroderma	0.000147	0.000677	CcSEcCtD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000146	0.00201	CbGpPWpGaD
Dabrafenib—Urethral disorder—Methotrexate—systemic scleroderma	0.000146	0.000676	CcSEcCtD
Dabrafenib—Diarrhoea—Lisinopril—systemic scleroderma	0.000146	0.000675	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—systemic scleroderma	0.000144	0.000664	CcSEcCtD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000143	0.00196	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000143	0.00196	CbGpPWpGaD
Dabrafenib—RAF1—Leptin signaling pathway—IL1B—systemic scleroderma	0.000142	0.00195	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000142	0.00195	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—TNFAIP3—systemic scleroderma	0.000142	0.00194	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000141	0.00194	CbGpPWpGaD
Dabrafenib—Dizziness—Lisinopril—systemic scleroderma	0.000141	0.000653	CcSEcCtD
Dabrafenib—Nausea—Mycophenolic acid—systemic scleroderma	0.000141	0.000651	CcSEcCtD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.00014	0.00193	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—BLK—systemic scleroderma	0.00014	0.00192	CbGpPWpGaD
Dabrafenib—Eye disorder—Methotrexate—systemic scleroderma	0.00014	0.000644	CcSEcCtD
Dabrafenib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000637	CcSEcCtD
Dabrafenib—ABCB1—lung—systemic scleroderma	0.000137	0.00726	CbGeAlD
Dabrafenib—Vomiting—Lisinopril—systemic scleroderma	0.000136	0.000628	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—systemic scleroderma	0.000135	0.000626	CcSEcCtD
Dabrafenib—BRAF—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000135	0.00186	CbGpPWpGaD
Dabrafenib—Immune system disorder—Methotrexate—systemic scleroderma	0.000135	0.000623	CcSEcCtD
Dabrafenib—Rash—Lisinopril—systemic scleroderma	0.000135	0.000622	CcSEcCtD
Dabrafenib—Dermatitis—Lisinopril—systemic scleroderma	0.000135	0.000622	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000135	0.000621	CcSEcCtD
Dabrafenib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000134	0.00062	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—systemic scleroderma	0.000134	0.00062	CcSEcCtD
Dabrafenib—Chills—Methotrexate—systemic scleroderma	0.000134	0.000619	CcSEcCtD
Dabrafenib—Headache—Lisinopril—systemic scleroderma	0.000134	0.000618	CcSEcCtD
Dabrafenib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000612	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—systemic scleroderma	0.000132	0.000612	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—systemic scleroderma	0.000132	0.000612	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—systemic scleroderma	0.000132	0.000609	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000132	0.000607	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—systemic scleroderma	0.000131	0.000604	CcSEcCtD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.00013	0.00179	CbGpPWpGaD
Dabrafenib—Erythema—Methotrexate—systemic scleroderma	0.00013	0.0006	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—systemic scleroderma	0.00013	0.0006	CcSEcCtD
Dabrafenib—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.00013	0.00178	CbGpPWpGaD
Dabrafenib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000592	CcSEcCtD
Dabrafenib—Nausea—Lisinopril—systemic scleroderma	0.000127	0.000586	CcSEcCtD
Dabrafenib—Oedema—Prednisone—systemic scleroderma	0.000127	0.000586	CcSEcCtD
Dabrafenib—Infection—Prednisone—systemic scleroderma	0.000126	0.000582	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—systemic scleroderma	0.000126	0.000581	CcSEcCtD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000126	0.00172	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SELP—systemic scleroderma	0.000125	0.00171	CbGpPWpGaD
Dabrafenib—Nervous system disorder—Prednisone—systemic scleroderma	0.000124	0.000575	CcSEcCtD
Dabrafenib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000572	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—systemic scleroderma	0.000123	0.000569	CcSEcCtD
Dabrafenib—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000123	0.00169	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000123	0.00169	CbGpPWpGaD
Dabrafenib—Hyperhidrosis—Prednisone—systemic scleroderma	0.000123	0.000567	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—systemic scleroderma	0.000123	0.000566	CcSEcCtD
Dabrafenib—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000122	0.00168	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000122	0.00167	CbGpPWpGaD
Dabrafenib—Anaemia—Methotrexate—systemic scleroderma	0.00012	0.000555	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—MMP9—systemic scleroderma	0.00012	0.00165	CbGpPWpGaD
Dabrafenib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000119	0.00055	CcSEcCtD
Dabrafenib—RAF1—Developmental Biology—RHOB—systemic scleroderma	0.000119	0.00163	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—NOS3—systemic scleroderma	0.000119	0.00163	CbGpPWpGaD
Dabrafenib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000545	CcSEcCtD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000118	0.00162	CbGpPWpGaD
Dabrafenib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000545	CcSEcCtD
Dabrafenib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000542	CcSEcCtD
Dabrafenib—RAF1—Hemostasis—RHOB—systemic scleroderma	0.000117	0.0016	CbGpPWpGaD
Dabrafenib—Leukopenia—Methotrexate—systemic scleroderma	0.000116	0.000537	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000116	0.000534	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—systemic scleroderma	0.000115	0.00053	CcSEcCtD
Dabrafenib—LIMK1—Immune System—CTLA4—systemic scleroderma	0.000115	0.00157	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MMP2—systemic scleroderma	0.000114	0.00157	CbGpPWpGaD
Dabrafenib—Cough—Methotrexate—systemic scleroderma	0.000113	0.000524	CcSEcCtD
Dabrafenib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000514	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—systemic scleroderma	0.000111	0.000511	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—systemic scleroderma	0.000111	0.000511	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—systemic scleroderma	0.00011	0.00051	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00011	0.000508	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—systemic scleroderma	0.000109	0.000505	CcSEcCtD
Dabrafenib—Constipation—Prednisone—systemic scleroderma	0.000109	0.000501	CcSEcCtD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000109	0.00149	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000108	0.00148	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000106	0.00146	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—CSK—systemic scleroderma	0.000106	0.00146	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL1B—systemic scleroderma	0.000106	0.00146	CbGpPWpGaD
Dabrafenib—Infection—Methotrexate—systemic scleroderma	0.000105	0.000487	CcSEcCtD
Dabrafenib—BRAF—Disease—SMAD7—systemic scleroderma	0.000105	0.00145	CbGpPWpGaD
Dabrafenib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000104	0.00048	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000104	0.00048	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000104	0.000479	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—systemic scleroderma	0.000103	0.000476	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000103	0.000474	CcSEcCtD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000101	0.00138	CbGpPWpGaD
Dabrafenib—Abdominal pain—Prednisone—systemic scleroderma	0.0001	0.000463	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—systemic scleroderma	0.0001	0.000463	CcSEcCtD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.0001	0.00137	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ITGAM—systemic scleroderma	9.98e-05	0.00137	CbGpPWpGaD
Dabrafenib—Hypotension—Methotrexate—systemic scleroderma	9.91e-05	0.000458	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.67e-05	0.000446	CcSEcCtD
Dabrafenib—BRAF—Disease—TGFBI—systemic scleroderma	9.64e-05	0.00132	CbGpPWpGaD
Dabrafenib—Insomnia—Methotrexate—systemic scleroderma	9.6e-05	0.000443	CcSEcCtD
Dabrafenib—RAF1—TCR Signaling Pathway—TGFB1—systemic scleroderma	9.54e-05	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	9.49e-05	0.0013	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-DQB1—systemic scleroderma	9.44e-05	0.0013	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	9.42e-05	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	9.37e-05	0.00129	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Prednisone—systemic scleroderma	9.35e-05	0.000432	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—systemic scleroderma	9.22e-05	0.000426	CcSEcCtD
Dabrafenib—RAF1—Adaptive Immune System—CSK—systemic scleroderma	9.17e-05	0.00126	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	9.16e-05	0.000423	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—systemic scleroderma	9.15e-05	0.000422	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—systemic scleroderma	9.11e-05	0.000421	CcSEcCtD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	9.01e-05	0.00124	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ITGAM—systemic scleroderma	8.98e-05	0.00123	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD247—systemic scleroderma	8.98e-05	0.00123	CbGpPWpGaD
Dabrafenib—Pruritus—Prednisone—systemic scleroderma	8.98e-05	0.000415	CcSEcCtD
Dabrafenib—LIMK1—Immune System—IL1A—systemic scleroderma	8.96e-05	0.00123	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD40LG—systemic scleroderma	8.91e-05	0.00122	CbGpPWpGaD
Dabrafenib—Diarrhoea—Prednisone—systemic scleroderma	8.69e-05	0.000401	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.68e-05	0.000401	CcSEcCtD
Dabrafenib—RAF1—Adaptive Immune System—CD247—systemic scleroderma	8.62e-05	0.00118	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MMP9—systemic scleroderma	8.57e-05	0.00118	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	8.43e-05	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TNFAIP3—systemic scleroderma	8.41e-05	0.00115	CbGpPWpGaD
Dabrafenib—Dizziness—Prednisone—systemic scleroderma	8.39e-05	0.000388	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—systemic scleroderma	8.39e-05	0.000387	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—systemic scleroderma	8.39e-05	0.000387	CcSEcCtD
Dabrafenib—BRAF—MAPK Signaling Pathway—TGFB1—systemic scleroderma	8.37e-05	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MMP9—systemic scleroderma	8.08e-05	0.00111	CbGpPWpGaD
Dabrafenib—Vomiting—Prednisone—systemic scleroderma	8.07e-05	0.000373	CcSEcCtD
Dabrafenib—Rash—Prednisone—systemic scleroderma	8e-05	0.00037	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—systemic scleroderma	8e-05	0.000369	CcSEcCtD
Dabrafenib—RAF1—Adaptive Immune System—BLK—systemic scleroderma	7.98e-05	0.0011	CbGpPWpGaD
Dabrafenib—Headache—Prednisone—systemic scleroderma	7.95e-05	0.000367	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—systemic scleroderma	7.82e-05	0.000361	CcSEcCtD
Dabrafenib—BRAF—Disease—HSPG2—systemic scleroderma	7.69e-05	0.00106	CbGpPWpGaD
Dabrafenib—Asthenia—Methotrexate—systemic scleroderma	7.61e-05	0.000352	CcSEcCtD
Dabrafenib—Nausea—Prednisone—systemic scleroderma	7.54e-05	0.000348	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—systemic scleroderma	7.51e-05	0.000347	CcSEcCtD
Dabrafenib—RAF1—MAPK Signaling Pathway—IL1B—systemic scleroderma	7.45e-05	0.00102	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CSK—systemic scleroderma	7.42e-05	0.00102	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMAD7—systemic scleroderma	7.38e-05	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SMAD7—systemic scleroderma	7.29e-05	0.001	CbGpPWpGaD
Dabrafenib—Diarrhoea—Methotrexate—systemic scleroderma	7.26e-05	0.000335	CcSEcCtD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.14e-05	0.00098	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TGFB1—systemic scleroderma	7.06e-05	0.00097	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	7.02e-05	0.000964	CbGpPWpGaD
Dabrafenib—Dizziness—Methotrexate—systemic scleroderma	7.02e-05	0.000324	CcSEcCtD
Dabrafenib—BRAF—Disease—CD247—systemic scleroderma	6.98e-05	0.000958	CbGpPWpGaD
Dabrafenib—Vomiting—Methotrexate—systemic scleroderma	6.75e-05	0.000311	CcSEcCtD
Dabrafenib—Rash—Methotrexate—systemic scleroderma	6.69e-05	0.000309	CcSEcCtD
Dabrafenib—RAF1—Signaling by GPCR—RHOB—systemic scleroderma	6.69e-05	0.000918	CbGpPWpGaD
Dabrafenib—Dermatitis—Methotrexate—systemic scleroderma	6.68e-05	0.000309	CcSEcCtD
Dabrafenib—RAF1—Disease—TGFBI—systemic scleroderma	6.67e-05	0.000916	CbGpPWpGaD
Dabrafenib—Headache—Methotrexate—systemic scleroderma	6.65e-05	0.000307	CcSEcCtD
Dabrafenib—RAF1—Adaptive Immune System—CTLA4—systemic scleroderma	6.54e-05	0.000897	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	6.43e-05	0.000882	CbGpPWpGaD
Dabrafenib—Nausea—Methotrexate—systemic scleroderma	6.3e-05	0.000291	CcSEcCtD
Dabrafenib—SLCO1B3—Metabolism—HSPG2—systemic scleroderma	6.25e-05	0.000857	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	5.79e-05	0.000795	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RHOB—systemic scleroderma	5.71e-05	0.000784	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CSK—systemic scleroderma	5.56e-05	0.000764	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP2—systemic scleroderma	5.53e-05	0.000759	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IRF5—systemic scleroderma	5.47e-05	0.000752	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.41e-05	0.000743	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HSPG2—systemic scleroderma	5.38e-05	0.000739	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	5.38e-05	0.000739	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HSPG2—systemic scleroderma	5.32e-05	0.00073	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IRF8—systemic scleroderma	5.23e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ITGAM—systemic scleroderma	5.23e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD247—systemic scleroderma	5.23e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	5.22e-05	0.000717	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CSK—systemic scleroderma	5.2e-05	0.000714	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CSK—systemic scleroderma	5.14e-05	0.000705	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMAD7—systemic scleroderma	5.11e-05	0.000701	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40LG—systemic scleroderma	5.08e-05	0.000698	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MMP1—systemic scleroderma	5e-05	0.000686	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	4.99e-05	0.000685	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	4.95e-05	0.00068	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TNFAIP3—systemic scleroderma	4.9e-05	0.000673	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BLK—systemic scleroderma	4.84e-05	0.000665	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD247—systemic scleroderma	4.83e-05	0.000663	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CTGF—systemic scleroderma	4.73e-05	0.00065	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—systemic scleroderma	4.68e-05	0.000642	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.65e-05	0.000638	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	4.2e-05	0.000576	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—systemic scleroderma	4.15e-05	0.00057	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.1e-05	0.000563	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTLA4—systemic scleroderma	3.96e-05	0.000544	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RHOB—systemic scleroderma	3.95e-05	0.000542	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP2—systemic scleroderma	3.94e-05	0.000541	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HSPG2—systemic scleroderma	3.89e-05	0.000533	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HSPG2—systemic scleroderma	3.72e-05	0.000511	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS3—systemic scleroderma	3.62e-05	0.000498	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CSK—systemic scleroderma	3.6e-05	0.000494	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EDN1—systemic scleroderma	3.41e-05	0.000469	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQB1—systemic scleroderma	3.26e-05	0.000448	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CTGF—systemic scleroderma	3.18e-05	0.000437	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1A—systemic scleroderma	3.1e-05	0.000426	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—systemic scleroderma	3.08e-05	0.000423	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—systemic scleroderma	2.96e-05	0.000407	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CTGF—systemic scleroderma	2.94e-05	0.000404	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EDN1—systemic scleroderma	2.91e-05	0.0004	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—systemic scleroderma	2.54e-05	0.000348	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.46e-05	0.000338	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—systemic scleroderma	2.44e-05	0.000335	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	2.41e-05	0.000331	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—systemic scleroderma	2.4e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—systemic scleroderma	2.33e-05	0.00032	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.1e-05	0.000288	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—systemic scleroderma	2.06e-05	0.000283	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EDN1—systemic scleroderma	2.02e-05	0.000277	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—systemic scleroderma	1.99e-05	0.000274	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CTGF—systemic scleroderma	1.83e-05	0.000251	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—systemic scleroderma	1.78e-05	0.000244	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—systemic scleroderma	1.75e-05	0.000241	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—systemic scleroderma	1.68e-05	0.00023	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—systemic scleroderma	1.62e-05	0.000222	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CTGF—systemic scleroderma	1.59e-05	0.000219	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—systemic scleroderma	1.42e-05	0.000196	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—systemic scleroderma	1.38e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—systemic scleroderma	1.38e-05	0.000189	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.29e-05	0.000178	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—systemic scleroderma	1.28e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—systemic scleroderma	1.23e-05	0.000169	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—systemic scleroderma	1.17e-05	0.000161	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—systemic scleroderma	1.16e-05	0.000159	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—systemic scleroderma	9.86e-06	0.000135	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CTGF—systemic scleroderma	9.81e-06	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—systemic scleroderma	8.12e-06	0.000112	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—systemic scleroderma	7.95e-06	0.000109	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—systemic scleroderma	6.93e-06	9.51e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—systemic scleroderma	4.27e-06	5.86e-05	CbGpPWpGaD
